本帖最后由 老马 于 2012-1-13 21:20 编辑 " [% ]3 }! y. k( _! J1 H! R; z2 m
2 e& y6 S6 C$ I0 Q0 H爱必妥和阿瓦斯丁的比较
, X }8 Z; u& a' h% o4 S f, F
5 W) F* Z4 L( [) U6 t
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
# ` D% s& a* w0 I; D- g' _* d
6 | ]& u/ O; R* g
. l/ `0 f @' v9 p: U
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/0 k- j# v" u0 R# a1 g
==================================================
! ^$ `$ Q$ F9 r9 c0 W0 g$ D3 nOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
- m; O6 z" f) E5 g& M5 f. UPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.* K4 g1 \( g7 y' @; G0 r
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported./ @& S( m2 A; o4 U6 f1 u2 _
|